Positive Proof of Concept for NutriLeads Key Ingredient

53a38dad-9600-4b5d-b8ca-7a91174f66b9articleimage.jpg

02 Jan 2016 --- Nutrition and health start-up NutriLeads is celebrating the beginning of 2017 following the positive findings of a proof of concept study for humans in connection with the lead ingredient Immuno Modulatory Plant Polysaccharide-1(IMPP-1). 

Clinical research company analyze & realize GmbH, the partner in the clinical study, says IMPP-1  is safe, well tolerated and supports immune function in humans.

NutriLeads develops nutritional ingredients for application in health-promoting food products. Initially founded in 2012 based upon an invention originating from Unilever, NutriLeads closed a successful seed financing round with an investor syndicate comprising Thuja Capital, DSM Venturing BV, PPM Oost and Shift Invest in 2015 and is currently discussing a series A financing.

As a clinical research organization and consulting firm specialized in natural health products, analyze & realize GmbH was the selected partner to conduct the clinical study at its own study center in Berlin. In an overall project duration of one year, a&r’s R&D clinical department investigated IMPP-1 in healthy humans and proved with success the concept of the natural ingredient being supportive of immune function in humans.

NutriLeads is developing this patented ingredient for different food applications including dietary supplements, medical food and functional food to reach various target populations. 

IMPP-1 can be sustainably sourced from food crops.
 
The results of the first proof of concept study with IMPP-1 in healthy volunteers were evaluated by an international group of key opinion leaders from industry and academia. The experts concluded that the results demonstrate excellent tolerability and safety characteristics and significant and dose dependent stimulation of the immune system.
 
“The positive result in first proof of concept study in healthy volunteers provides the necessary confidence to go full speed ahead with our ambitious development program including several clinical trials to support the use of this proprietary ingredient from sustainable sources as dietary supplement and for application in specialized functional and medical food products”, says Ruud Albers, PhD, CEO of NutriLeads.
 
NutriLeads, as consortium leader, and four European partners – including a&r – have been awarded a €2 million Eurostars project called NIMF. 

The consortium will develop NutriLeads’ proprietary ingredient IMPP-1 into a new ingredient for medical food products to fight impaired immune function as a result of malnutrition (particularly common in a variety of patient groups).

RELATED ARTICLES
Homepicture

Seventure Partners’ microbiome portfolio nears critical milestones 

18 Dec 2017 Seventure Partners, one of Europe’s ...

Homepicture

Soylent returns to Silicon Valley roots with retail expansion

15 Dec 2017 Rosa Foods, the makers of Soylent, has announced ...

Homepicture

Vitafoods Europe to examine mainstreaming of personalized nutrition

13 Dec 2017 One of the major issues to be discussed at ...

Homepicture

Frutarom finalizes AB-Fortis micro-encapsulation technology acquisition

13 Dec 2017 Frutarom has acquired AB-Fortis activities, ...

Homepicture

Kappa Bioscience moves to expand vitamin K2 presence in US with new appointments

13 Dec 2017 Kappa Bioscience AS, maker of K2Vital vitamin K2 ...